DIRS.INFO The most relevant business & tech news

☆ Obesity Drug Demand Outstrips Supply
▼ + stars: | 2023-11-02 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovEli Lilly ’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk , which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications.

Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Eli Lilly ’, Mounjaro, Lilly Organizations: Drug Administration, Denmark’s, Denmark’s Novo Nordisk Locations: Denmark’s Novo

☆ Obesity revolution gorges on dialysis maker
▼ + stars: | 2023-10-11 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

REUTERS/Megan Jelinger Acquire Licensing RightsLONDON, Oct 11 (Reuters Breakingviews) - Kidney dialysis kit-makers look set to be the latest victim of the obesity drug boom. On Wednesday, shares in Germany-listed Fresenius Medical Care (FMEG.DE) fell 20% after a medical trial showed a Novo Nordisk (NOVOb.CO) drug can reduce the risk of kidney failure. Diabetes and obesity drugs are showing their fringe benefits. In a recent drug trial, Wegovy, an obesity remedy made by Denmark’s Novo Nordisk, reduced the incidence of serious cardiovascular events like strokes and heart attacks by 20% in overweight patients. The collapse in Fresenius Medical Care’s share price looks appropriate.

Persons: Dawn, Megan Jelinger, Michael Sen, Danish drugmaker, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, Novo Nordisk, Denmark’s Novo Nordisk, Fresenius, Thomson Locations: Findlay , Ohio, U.S, Germany, Fresenius, Vamed, Danish

The falling shares mean that Mr. Arnault (now worth about $195 billion, Forbes says) dropped to the second-richest person in the world in June, eclipsed by Elon Musk. Mr. Arnault has broadened LVMH beyond extravagant playthings into the world of experiences, acquiring over 50 grand hotels and resorts. Mr. Arnault’s changes mean he doesn’t have to retire next year as originally expected. The French media is full of headlines comparing the Arnaults to the Roys, the fictional family in the HBO series. There are TikTok videos explaining why the Arnaults are “the real ‘Succession’ family.” The family hates this talk, and takes pains to play down parallels to the show.

Persons: Arnault, Forbes, Elon Musk, LVMH, —, gobbling, Delphine, Dior Organizations: Denmark’s Novo Nordisk, HBO

☆ The obesity drug boom is just getting started: podcast
▼ + stars: | 2023-09-05 | by ( Aimee Donnellan | ) www.reuters.com time to read: +1 min

A 0.25 mg injection pen of Novo Nordisk’s weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration Acquire Licensing RightsLONDON, Sept 5 (Reuters Breakingviews) - Over 1 bln people are obese, the WHO reckons. Denmark’s Novo Nordisk is ahead of the pharma pack with its Wegovy weight-loss drug. Listen to the podcastFollow @aimeedonnellan on XSubscribe to Breakingviews’ podcasts, Viewsroom and The Exchange. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Victoria Klesty, Lars Jorgensen, Oliver Taslic Organizations: REUTERS, Reuters, WHO, Denmark’s, Denmark’s Novo Nordisk, pharma, Thomson Locations: Oslo, Norway, Victoria, Denmark’s Novo

Search resuls for: "Denmark’s Novo"

4 mentions found